Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Are the Projected Market Size and Growth Rates for the Non-Proliferative Diabetic Retinopathy Market From 2025 To 2029?
The market for non-proliferative diabetic retinopathy has experienced significant growth in the past few years. The market value is set to increase from $2.62 billion in 2024 to $2.83 billion in 2025, that’s an 8.1% compound annual growth rate (CAGR). The upward trend observed in the previous years can be linked to factors such as a rise in diabetes cases, an aging population, elevated awareness, advancements in research, changes in lifestyle and better management of diabetes.
The market for non-proliferative diabetic retinopathy is forecasted to experience substantial growth in the coming years, expanding to $3.77 billion by 2029 with a 7.4% Compound Annual Growth Rate (CAGR). Factors contributing to this progress during the projected period includes the rising use of telemedicine, the advent of innovative therapeutics, the integration of artificial intelligence, increased funding in research and development, and the broadening of healthcare infrastructure. Major trends projected for the forecast period encompass the escalated use of artificial intelligence for screening and diagnosis, the growing necessity for telemedicine and remote observation solutions, the emergence of tailored medicine approaches for treating diabetic retinopathy, an increased emphasis on preventive measures and early intervention, along with the expanding role of patient-oriented care models in managing diabetic retinopathy.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15620&type=smp
What Are the Major Market Drivers Behind the Rising Adoption of Non-Proliferative Diabetic Retinopathy Market?
The growth of the non-proliferative diabetic retinopathy market is predicted to be driven by the growing occurrence of diabetes. This long-term metabolic disorder makes the body either not produce enough insulin, or makes the cells resistant to its effects, leading to high blood sugar levels. Sedentary living, poor dietary choices, and genetic factors are all known to cause it. Diabetes can lead to non-proliferative diabetic retinopathy, a condition where the retinal blood vessels are damaged primarily due to prolonged high blood sugar levels, potentially causing vision loss and even blindness. In June 2024, the UK-based government department National Health Service announced that in 2023, an additional 549,000 individuals at risk of developing type 2 diabetes were identified in England. This brings the total number of people with pre-diabetes registered with a GP to 3,615,330, showcasing a striking rise from 3,065,825 in 2022 – an increase of nearly 20%. Accordingly, the rising incidence of diabetes is fuelling the expansion of the non-proliferative diabetic retinopathy market.
Which Key Market Segments Comprise the Non-Proliferative Diabetic Retinopathy Market and Drive Its Revenue Growth?
The non-proliferative diabetic retinopathymarket covered in this report is segmented –
1) By Treatment Type: Anti-Vascular Endothelial Growth Factor (VEGF) Therapy; Intraocular Steroid Injection; Laser Surgery; Vitrectomy
2) By Disease Severity Level: Mild Non-Proliferative Diabetic Retinopathy; Moderate Non-Proliferative Diabetic Retinopathy; Severe Non-Proliferative Diabetic Retinopathy
3) By End-User: Hospitals; Specialty Clinics; Ambulatory Surgical Centers; Other End-Users
Subsegments:
1) By Anti-Vascular Endothelial Growth Factor (Vegf) Therapy: Bevacizumab (Avastin); Ranibizumab (Lucentis); Aflibercept (Eylea); Pegaptanib (Macugen)
2) By Intraocular Steroid Injection: Triamcinolone Acetonide; Dexamethasone Implant (Ozurdex); Fluocinolone Acetonide Implant (Iluvien)
3) By Laser Surgery: Focal Laser Photocoagulation; Panretinal Photocoagulation
4) By Vitrectomy: Pars Plana Vitrectomy (Ppv); Membrane Peeling Vitrectomy; Phaco-Vitrectomy (Combined Cataract And Vitrectomy Surgery)
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=15620&type=smp
Which Areas Are Leading Regions in the Non-Proliferative Diabetic Retinopathy Market Expansion Across the Globe?
North America was the largest region in the non-proliferative diabetic retinopathy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the non-proliferative diabetic retinopathy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Are the Strategic Trends Steering theNon-Proliferative Diabetic Retinopathy Market Direction?
In the non-proliferative diabetic retinopathy market, leading companies are leveraging AI technology to enhance patient outcomes and progress ophthalmic imaging. AI-enabled cameras for ophthalmic imaging are devices integrated with AI algorithms that help in capturing, analyzing, and understanding eye images for diagnostic and treatment purposes. For example, Optomed, a medical tech firm from Finland, launched its Optomed Aurora AEYE, a handheld AI fundus camera, in May 2024. This camera, designed to detect more than mild diabetic retinopathy quickly, merges the convenience of a handheld device with AI’s power to offer superior retinal images necessary for early detection and observing various eye conditions. The Optomed Aurora AEYE employs AI algorithms to aid healthcare professionals in interpreting retinal images, hence allowing for swift and accurate diagnosis of diseases such as diabetic retinopathy, glaucoma, and age-related macular degeneration.
View the full report here:
How Is the Non-Proliferative Diabetic Retinopathy Market Conceptually Defined?
Non-proliferative diabetic retinopathy (NPDR) is a common complication of diabetes mellitus that affects the retina, the light-sensitive tissue lining the back of the eye. NPDR is characterized by changes in the blood vessels of the retina due to prolonged exposure to high levels of blood sugar (hyperglycemia) associated with diabetes. It is managed through a combination of medical interventions, lifestyle modifications, and regular eye examinations to prevent disease progression and preserve vision.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15620
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model